CRMD vs. MLTX, MTSR, VKTX, MOR, KYMR, ALVO, IMVT, CRNX, CPRX, and HCM
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), Kymera Therapeutics (KYMR), Alvotech (ALVO), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs. Its Competitors
MoonLake Immunotherapeutics (NASDAQ:MLTX) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
In the previous week, CorMedix had 25 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 26 mentions for CorMedix and 1 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat CorMedix's score of 0.52 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
CorMedix has a net margin of 20.81% compared to MoonLake Immunotherapeutics' net margin of 0.00%. CorMedix's return on equity of 22.57% beat MoonLake Immunotherapeutics' return on equity.
CorMedix has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics presently has a consensus price target of $74.50, indicating a potential upside of 60.68%. CorMedix has a consensus price target of $17.14, indicating a potential upside of 47.28%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than CorMedix.
MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 5.3% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
CorMedix beats MoonLake Immunotherapeutics on 10 of the 16 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 7/3/2025 by MarketBeat.com Staff
